Stock Ratings / Health Care / PBH / insiders

AUPH (75) PHVS (63) RCUS (35) HCM (46) ⌘ Pro Terminal →

Prestige Consumer Healthcare Inc. (PBH) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$48.75 +2.01% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $49.04

Prestige Consumer Healthcare Inc. (PBH) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (55% profit margin, 14% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate) →

ROARABLE B • BUY Cap $2.31B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $49.04 (+0.60%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 22.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PBH)Realized 20D OHLCV Swing Band: ±6.2%

Deterministic 5-Pillar Attribution (72/100 Composite)

🔍 WHY PBH SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+18/20 pts (25% of score)

FRED Regime × Technicals: 22% of 52W Range • RSI-14 at 54.1 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk11/20 pts (-9 pt drag)

Balance-sheet & 10-K footnote risk deducts 9 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$48.23+3.5% Next Q

Q2 (-2Q)

Grade B-$49.92-4.2% Next Q

Q3 (-1Q)

Grade B-$47.80+2% Next Q

Current

Grade B$48.75+7% Hist 90D α

Trajectory: C+ (64) → B (72)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PBH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 72/100 (B) score, PBH faces multiple-compression risk if 12.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 52.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($48.53) or 200D SMA ($54.09) invalidates the momentum regime and cuts Target Base ($51.82) toward Bear Floor ($39.97).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PBH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PBH Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 72%NO 28%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

PBH Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (PBH)

No recent open-market Form 4 cluster sales or emergency dumps flagged on PBH. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (PBH Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PBH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.44%⚡ TESTING RESISTANCE

2026-10-30O $50.23H $50.23L $48.75C $48.75VOL 371.5K

RES: $49.68SUP: $44.62SMA50: $48.53SMA200: $54.09

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PBH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PBH Butterfly Map → + Track PBH →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

2.7%/yr Implied 5Y Growth

vs. -4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PBH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PBH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PBH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PBH)

Health Care Rank #75 of 1016 ⚔️ AUPH vs PBH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PBH vs. AUPH, PHVS, RCUS, HCM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Prestige Consumer Healthcare Inc. (PBH) ranks #75 by composite RQD confidence (72/100, grade B) and #236 by equity capitalization ($2.31B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while AUPH leads on capital efficiency and profitability with 16.5% ROIC and 88.5% gross margin. AUPH currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with PBH at 72/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PBH ACTIVE Prestige Consumer Healthcare Inc.	B	72/100	12.1x	54.7%	13.8%	+2.01%	$2.31B	Benchmark Subject
AUPH Aurinia Pharmaceuticals Inc	B	75/100	8.0x	88.5%	16.5%	-0.86%	$2.29B	/auph-vs-pbh →
PHVS Pharvaris N.V.	C	63/100	—	—	—	+2.32%	$2.34B	/phvs-vs-pbh →
RCUS Arcus Biosciences Inc.	D-	35/100	—	—	-35.0%	+1.20%	$2.37B	/rcus-vs-pbh →
HCM HUTCHMED (China) Limited	D	46/100	5.2x	—	-2.5%	+2.03%	$2.37B	/hcm-vs-pbh →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001295947

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Prestige Consumer Healthcare Inc. (PBH) reported GAAP revenue of $1.09B (-4.3% vs. FY2024 revenue of $1.14B , and -3.3% cumulative change since FY2023) , GAAP net income of $190.3M, operating cash flow of $257.6M, and free cash flow of $246.4M (+1.3% YoY). On the balance sheet, PBH closed FY2025 with $3.49B in total assets against $0 in total debt (Altman Z-Score: 2.21, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$1.09B	$190.3M	$257.6M	$246.4M	$3.49B	—
FY2024 (FY)	2025-03-31	$1.14B	$214.6M	$251.5M	$243.3M	$3.33B	$1.00B
FY2023 (FY)	2024-03-31	$1.13B	$209.3M	$248.9M	$248.9M	—	—

3. PBH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PBH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Prestige Consumer Healthcare Inc. (NYSE: PBH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $48.75 (+2.01% 1D, market cap $2.31B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, PBH ranks #75 in composite RQD confidence.

How does PBH compare to AUPH and PHVS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBH carries a Roarable B (72/100 RQD), trailing P/E of 12.1x, gross margin of 54.7%, and ROIC of 13.8%. By comparison, AUPH (Aurinia Pharmaceuticals Inc) holds a B grade (75/100 RQD, P/E 8.0x, ROIC 16.5%, cap $2.29B) and PHVS (Pharvaris N.V.) posts a C grade (63/100 RQD, P/E N/A, ROIC —, cap $2.34B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while AUPH leads on capital efficiency (16.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PBH?

Per PBH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001295947), Prestige Consumer Healthcare Inc. generated $1.09B in revenue (-4.3% YoY), $190.3M in net income, and $246.4M in free cash flow against $3.49B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PBH trading relative to its 50-day, 200-day, and 52-week technical levels?

PBH last traded at $48.75 (+2.01% on volume of 343,426 shares), positioning the stock +0.45% above its 50-day simple moving average ($48.53) and -9.87% below its 200-day simple moving average ($54.09). Across its 52-week range of $42.62 to $71.07, PBH sits at the 21.5% percentile with a 14-day RSI of 54.1 (NEUTRAL RANGE) and an implied next-earnings move of ±6.2% ($45.73 to $51.77).

PBH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are PBH insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies PBH leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Direct Sub-Reports: PBH RQD Cockpit PBH 12M Forecast PBH Earnings & Move PBH Dividends & DRIP PBH Insiders & 13F PBH Whale Options PBH Profit Sankey PBH News & Why